To explore the clinical efficacy of Fuzheng Anzhong Decoction combined with sorafenib(SOR) in the treatment of patients with intermediate-to-advanced liver cancer after transcatheter arterial chemoembolization(TACE).Methods:A total of 100 patients with intermediate-to-advanced liver cancer who underwent TACE at the Oncology Department of Bozhou Hospital of Traditional Chinese Medicine from January to December 2021 were selected.They were randomly divided into a control group and an observation group，with 50 cases in each group.The control group was treated with SOR alone，while the observation group was treated with Fuzheng Anzhong Decoction combined with SOR.The treatment efficacy was evaluated after three courses of treatment，and the patients were followed up for one year.The changes in traditional Chinese medicine(TCM) syndrome scores，liver function，renal function，tumor markers，and levels of inflammatory mediators before and after treatment were compared between the two groups.The one-year survival rate and drug safety of the patients were also analyzed.Results:The disease control rates in the control group and the observation group were 24.00% and 56.00%，respectively(P<0.05).After treatment，the TCM syndrome scores and serum indicators including glutamic oxaloacetic transaminase(GOT)，glutamic pyruvic transaminase(GPT)，albumin(ALB)，and total bilirubin(TB) decreased compared to those before treatment in both groups，with the control group being higher than the observation group(all P<0.05).The serum creatinine(Cr) and blood urea nitrogen(BUN) levels increased in both groups after treatment compared to those before treatment，with the control group being lower than the observation group，but the difference was not statistically significant(P>0.05).The one-year survival rates of the control group and the observation group during the follow-up period were 24.00% and 42.00%，respectively，with a significant difference between the groups(χ2=8.72，P=0.001 8).The levels of serum tumor-specific growth factor(TSGF)，alpha-fetoprotein(AFP)，vascular endothelial growth factor(VEGF)，tumor necrosis factor-alpha(TNF-α)，and interleukin-6(IL-6) decreased after treatment compared to those before treatment in both groups，with the control group being higher than the observation group(P<0.05).Conclusion:Fuzheng Anzhong Decoction combined with SOR is an effective regimen for treating patients with intermediate-to-advanced liver cancer after TACE.Compared with SOR alone，it can effectively regulate serum tumor markers and levels of inflammatory mediators without increasing the risk of drug treatment.